References
- Epstein S, Cryer B, Ragi S et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003;19:781–9
- United States Pharmacopeia. Available at: http://www.usp.org [accessed 1 April 2004]
- Aïache JM. In: Biofarmacia. Manual Moderno, Mexico, 1983
- Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003;25:2875–90
- Suri S, Monkkonen J, Taskinen M et al. Nitrogen-containing biphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of biphosphonate-induced gastrointestinal toxicity. Bone 2001;29:336–43
- Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate tablets: possible mechanisms. Dig Dis Sci 1998;43:1998–2002
- Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-biphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193–202
- Sharpe M, Noble S, Spencer C. Alendronate: an update of its use in osteoporosis. Drugs 2001;61:999–1039
- Doménech J. In: Biofarmacia y Farmacocinética, Vol. 2. Editorial Síntesis, Madrid, 1998
- Epstein S, Cryer B, Ragi S et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003;19:781–9
- Rägo L. Ensuring access to drug products that are of acceptable quality. WHO Pilot Procurement Quality and Sourcing (‘prequalification’) project. World Health Organization Web site. Available at: http://www.who.int/medicines/organization/par/ briefing/9prequalification.ppt [Accessed 4 September 2003]
- Ministerio de Salud, Peru, Web site. Available at: http://www.minsa.gob.pe/infodigemid/alertas [accessed on 24 March 2004]